Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

$170.2 million for the same periods in 2011.Early Retirement of Debt
In August 2012, Isis issued $201.3 million of 2 ¾% convertible senior notes due 2019 (2 ¾% Notes).  In September 2012, Isis used a substantial portion of the net proceeds from the issuance of these notes to redeem the entire $162.5 million of the Company's 2 ⅝% convertible subordinated notes (2 ⅝% Notes). As a result of the early redemption of the 2 ⅝% Notes, Isis recognized a $4.8 million loss primarily related to a non-cash write-off of the unamortized portion of the debt discount and debt issuance costs. 

Gain on Investment in Regulus Therapeutics Inc.
In October 2012, Regulus Therapeutics, Inc., a company Isis co-founded, completed an initial public offering.  In the fourth quarter, as a result of the IPO, Isis recorded an $18.4 million gain to reflect the Company's change in its ownership percentage in Regulus. Also in the fourth quarter, Isis stopped using the equity method to account for its investment in Regulus and instead began accounting for it at fair value.  Isis now owns approximately seven million shares, or 17%, of Regulus' common stock on a fully diluted basis. 

Net Loss
Isis reported a net loss of $2.6 million and $65.5 million for the three and twelve months ended December 31, 2012, respectively, compared to $20.0 million and $84.8 million for the same periods in 2011.  Basic and diluted net loss per share for the three and twelve months ended December 31, 2012 was $0.03 per share and $0.65 per share, compared to $0.20 per share and $0.85 per share for the same periods in 2011.  In 2012, Isis' net loss was significantly lower than 2011 primarily due to the $18.4 million gain from its investment in Regulus and the related $9.1 million tax benefit offset, in part, by an increase in Isis' net operating loss, the $4.8 million loss on Isis' early retirement of its 2 ⅝% N
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
6. Kewaunee Scientific Reports Improved Results for Third Quarter
7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
8. Questcor Reports Fourth Quarter and Full Year 2012 Results
9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
(Date:7/28/2014)... ResMed (NYSE: RMD ), innovatore e pioniere ... respiratori del sonno (SDB) e altre patologie croniche del ... il produttore Taiwanese di dispositivi medicali, APEX Medical Corp. ... in testa, che violano i brevetti, utilizzate con l,APEX ... Corte Regionale Distrettuale di Monaco , ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2
(Date:7/28/2014)... The report, “Blowing Agents Market by ... and Forecasts to 2019” defines and segments the ... of the global consumption volume and value. , ... 39 figures spread through 226 Pages and in-depth ... , Blowing agents are highly utilized materials as ...
(Date:7/28/2014)... for patients with one of the UK,s most common ... Chronic obstructive pulmonary disease (COPD) is the name for ... to long-term damage to the lungs. Often linked ... of all hospital admissions in the UK, with a ... they are discharged. , A team of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... -- Researchers from The University of Texas Health Science Center ... have identified a combination of pills that cures 9 of ... sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent ... patients, according to the study published today in The ... U.S. , Eric Lawitz, M.D., clinical professor in the ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The North America ... & antioxidants market in North America with analysis and forecast ... $539.9 million in 2012 to $812.7 million by 2018, at ... through the TOC of the North America Carotenoids & Antioxidants ... provided. It also provides a glimpse of the segmentation in ...
Breaking Medicine News(10 mins):Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4
... of Pharmaceutical Marketing Industry Due to New PhRMA ... 6 Pharmaceutical marketers are taking on the ... Systems, a unique marketing company whose integrated engagement ... the sector. In the past two years the ...
... A survey recently conducted by the Society of ... Compliance Association (HCCA) reveals that the declining economy may ... in business. In addition, this increased risk is ... risks are expected to at best hold steady, if ...
... /PRNewswire/ -- Akerman Senterfitt, one of the ... top 100 firms in the U.S., today announced that ... the auspices of the American Health Lawyers Association (AHLA) ... and issues concerning privilege and confidentiality. The live audiocast ...
... POINT, N.Y., Jan. 6 Akrimax Pharmaceuticals, LLC ... of pharmaceutical products for a global company beginning ... partners in a competitive process.Akrimax President Alan L. ... to acquire the Rouses Point facility which possesses ...
... KENILWORTH, N.J., Jan. 6 Schering-Plough Corporation (NYSE: ... results for the 2008 fourth quarter and full year on ... that day, Schering-Plough will conduct a conference call to review ... Fred Hassan, Schering-Plough,s chairman and CEO, and other members of ...
... for expanding role of patient flow automation PITTSBURGH, Jan. ... its clients, now more than 700 hospitals, solve their ... to increase capacity and improve patient flow is now ... have postponed building and expansion plans because of the ...
Cached Medicine News:Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 2Health News:Kyp Systems Takes on the Challenge of New Pharmaceutical Marketing Guidelines 3Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 2Health News:Legal and Ethical Violations Risks Seen Rising, But Not Resources to Control the Risk 3Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 2Health News:Akerman Senterfitt Hosts National Panel Discussion on Patient Safety Organizations 3Health News:Akrimax Pharmaceuticals Announces Manufacturing Partnership 2Health News:Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings 2Health News:TeleTracking Technologies to Focus on Growth 2Health News:TeleTracking Technologies to Focus on Growth 3
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
... be more comfortable, and you will too., ... secure and to avoid the knotty problems ... twill ties, consider the Dale® Tracheostomy Tube ... the narrow fastener tabs of the Dale® ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: